Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...

As biopharma and healthcare companies face a rapidly shifting regulatory environment, marketing and advisory firm Avalere ...

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...